Drug Profile
MK 8527
Alternative Names: MK-8527Latest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Antiretrovirals
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HIV-1 infections
Most Recent Events
- 06 Mar 2024 Merck Sharp & Dohme plans a phase I trial (In volunteers) (PO, Capsule) in April 2024 (NCT06295796)
- 31 Jan 2024 Merck completes a phase-I trial in HIV-1 infections (Treatment-naïve) in Romania and South Africa (PO) (NCT05494736)
- 08 Nov 2023 Phase-II clinical trials in HIV-1 infections (Prevention) in Israel, USA (PO) (NCT06045507)